These studies collectively demonstrate the exciting potential of combining HDAC inhibitors with nanomedicine strategies, offering a path toward more effective and precise epigenetic-based cancer therapies, which could significantly impact the treatment landscape for various types of cancer. The gene discussed is HDAC9; the disease is cancer.